US/UK/Canada

Share

Contacts

  • Bent U. Frandsen

    CEO


    +45 2222 1019
    http://www.expres2ionbio.com
  • Keith Alexander

    CFO


    +45 2222 1019
    http://www.expres2ionbio.com
    • Pick a time period -
    Tags ( Active)

    ExpreS2ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics

    ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS2ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new range of solutions for the next generation of vaccines, immunotherapy and diagnostics.The CRISPR/Cas9 gene editing technology was derived from a natural defence mechanism found in bacteria, and in recent years it has created a

    ExpreS2ion’s joint venture, AdaptVac, receives notice of allowance in the U.S. for its breast cancer vaccine patent

    ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that its joint venture AdaptVac has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step forward for the project and documenting the patentability of the virus-like-particle (VLP) technology platform. After final approval, the patent will be valid at least 20 years from the priority date, 15-01-2015.“This is a major

    ExpreS2ion’s core platform patent allowed in Canada

    ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in Canada and will be granted with expiry June 12, 2029.“With the patent allowance in Canada, ExpreS2ion has now successfully obtained patent protection of its ExpreS2 platform in all major markets of interest. Thereby the major initial goal for our ExpreS2 platform patent portfolio, which is fundamental to our business, has been reached," says Dr. Steen

    ExpreS2ion’s core platform patent allowed in India

    Hørsholm, Denmark, December 28, 2017 – Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in India and will be granted with expiry June 12, 2029.“Obtaining a strong patent protection in India, one of the world’s largest markets for vaccine technology, is an important step towards our goal to have the ExpreS2 platform protected in all major markets and consolidate our position as a global player. We

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media